Elmer’s introduces new adhesive
COLUMBUS, OH — Elmer’s Products, a supplier of adhesives, has introduced Elmer’s ProBond Advanced, a multi-service adhesive designed for mixed-material projects, to its line of products. The product provides the strength of polyurethane glue without the foam residue that could potentially ruin a project’s finished appearance, the company said.
"As trends, tastes and aspirations evolve, the brand that people grew up trusting is delivering a mixed-material formula as unique and versatile as their most creative home project ideas. Whether you’re working with stone, metal, ceramic, wood or glass, ‘opposites attract, as ProBond Advanced’s unique formula makes it easy to bond porous to non-porous materials," said Elmer’s product manager, Emily von Stein. "From do-it-yourself novices to experts, you can rely on ProBond Advanced to provide the heavy-duty strength and durability you need without the mess."
ProBond Advanced is nontoxic and 100% weatherproof, allowing project enthusiasts to use it safely indoors or outdoors any time of the year.
For best application, ProBond Advanced should when be used air, parts and glue are warmer than 60F. The adhesive also should be used on clean, dry and oil and grease-free surfaces. ProBond Advanced is recommended when bonding porous and semi-porous materials, like ceramic, wood, pottery and drywall to non-porous surfaces, such as glass, metal and stone.
No comments found
CVS Caremark’s MinuteClinic testing telehealth at 28 sites
WOONSOCKET, R.I. — Forging ahead on its longer-term goal of creating a national platform to support primary care, CVS Caremark plans to open up at least 150 new MinuteClinic locations this year and is now testing telehealth at more than two-dozen sites.
With a primary care physician shortage that is expected to reach 45,000 in 2020 and nearly half of patients indicating that they do not have a primary care physician, the role of MinuteClinic is no doubt becoming increasingly vital.
As noted during the company’s 2013 Analyst Day in December, the company is looking to increase access via such technology as telehealth, in addition to expanding its geographic footprint and non-acute services.
During Tuesday’s fourth-quarter conference call with analysts, president and CEO Larry Merlo said the company is now piloting telehealth at 28 sites in Los Angeles, San Diego and Orange County, Calif.
“Our California nurse practitioners are now providing patient care remotely through sophisticated video technology and audio equipment with licensed vocational nurses assisting patients,” Merlo said. “We plan to expand this exciting pilot to a second state later this year, and we look forward to the results.”
Merlo also said that during the fourth quarter, revenues at MinuteClinic rose more than 10% despite a tough comparison with a strong flu season in 2012.
During the quarter, the company opened 74 net-new clinics, including clinics in new states and markets, such as New Hampshire and the San Francisco/San Jose area, and hit a milestone of 800 total clinics in 28 states and Washington, D.C.
During 2014, the company plans to open 150 new MinuteClinic locations. By 2017, it expects to have about 1,500 clinic locations.
Two, national, leadership breakthroughs in a single month! CVS is beginning to re-establish its reputation as a leader in the race to transform pharmacies into critical points of entry into a national healthcare delivery system. First, came breaking the habit of selling tobacco. Now, from the company that first launched retail-affiliated clinics on a national scale, comes telemedicine--an innovation that could eventually connect 8,000 virtual points of entry to an integrated healthcare system for the 21st Century. Impressive. Ron Hammerle, Chairman Health Resources, Ltd. Tampa, Florida
CVS Caremark Q4 results rise to produce record year
WOONSOCKET, R.I. — CVS Caremark released on Tuesday fourth-quarter results, which came in at the high end of expectations and helped produce a record year, but as expected, among the key topics of discussion during the conference call with analysts was the company’s recent decision to stop selling tobacco products in all of its stores by Oct. 1.
“Last week we announced our decision to exit the tobacco category, a category that we believe is inconsistent with our growing role in the changing healthcare marketplace,” Larry Merlo, president and CEO, told analysts. “Simply put, this was the right decision at the right time. There is a far greater focus emerging on health outcomes, managing chronic disease and reducing costs, and exiting the tobacco category more closely aligns us with the goals of patients, clients and providers, positioning our company for future growth.”
Merlo made note of the overwhelmingly positive response across an array of key constituents, including customers, prospective and current clients, benefit consultants, legislators and policymakers, and public health and Medicaid officials.
“All of whom see the health benefits, as well as the role that pharmacy can play in advancing smoking cessation and better managing chronic disease,” Merlo said.
As reported, the move is expected to result in a loss of approximately $2 billion in revenues on an annual basis from the tobacco shopper. The $2 billion represents about 3% of earnings.
“When you look at that eight feet to 10 feet that tobacco commands today, there will be something replacing that space, and to be clear, it is not going to make up $2 billion in revenues, but it will be something. And there are some things that are being tested as we speak,” Merlo said when asked about its plans at retail and the steps it would take to help offset some of the loss.
Added Helena Foulkes, president of CVS/pharmacy, “We are seeing this tobacco decision as an opportunity to connect even more consumers as an expert in health and beauty and to build our loyalty with them. As we focus specifically on the front store, it is really around driving what we will call ‘smart growth’ and I think there it has three elements: taking ExtraCare to the next level, the second is focusing on our core strength in health and beauty, and the third is driving our store brand penetration.”
During the quarterly call with analysts, Merlo also provided analysts with a broad-reaching business update including:
• The impact of the Affordable Care Act and the role CVS Caremark can play in serving new customers and supporting health plans;
• Its joint venture with Cardinal Health to form the largest generic sourcing entity in the United States. The venture will help spur innovative purchasing strategies with generic manufacturers and is expected to be operational by July;
• The 2014 selling season, which has resulted in net-new wins of about $2 billion, excluding attrition in the Med D business. Merlo said that while it is too early to provide an update on the 2015 selling season, the company is “well-positioned” to both retain business and gain share; and
• The specialty pharmacy business, which posted a revenue increase of about 22% year over year. Merlo added that the company expects to see significant growth in the specialty space and is well-positioned to capitalize on the opportunity. Enter its acquisition in January of Coram, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group.
“This provides us with a new set of capabilities to manage not just the cost of infused drugs, but also to reduce the length of hospital stays and to help patients move from higher cost sites of service, like hospital outpatient centers, to more cost-effective locations, such as the patient’s home or a physician’s office,” Merlo said.
Furthermore, its new Specialty Connect offering is on schedule to roll out in 2014. Analogous to the Maintenance Choice program, Specialty Connect integrates mail and retail capabilities to provide both greater choice and convenience for members.
CVS Caremark’s MinuteClinic business, which posted a revenue increase of more than 10% during the quarter and reached a milestone with 800 total clinics in 28 states and Washington, D.C.
Net revenues for the three months ended Dec. 31 increased 4.6%, or $1.4 billion to $32.8 billion, up from $31.4 billion the year-ago period. For the year, total revenue rose 3% to $126.8 billion compared with $123.1 billion last year.
Revenues in the pharmacy services segment increased 5.2% to $19.6 billion during the quarter. This increase was primarily associated with drug cost inflation, new products and new clients in the specialty pharmacy business, the company stated. For the year, total revenue in the pharmacy services segment increased 3.8% to $76.2 billion
Revenues in the retail pharmacy segment increased 5.6% to $17.2 billion during the quarter. Same-store sales rose 4%, with pharmacy same-store sales up 6.8%. Front-end same-store sales decreased 1.9% due to softer traffic, which was partially offset by an increase in basket size, the company stated. For the year, total revenue in the retail pharmacy segment rose 3.1% to $65.6 billion. Same-store sales increased 1.7% for the year, with pharmacy same-store sales up 2.6% and front-end, same-store sales down 0.5%.
Income from continuing operations attributable to CVS Caremark for the three months increased 12.4% to $1.3 billion, compared with $1.1 billion in the year-ago period. Adjusted earnings per share from continuing operations attributable to CVS Caremark for the three months ended Dec. 31, 2013 and 2012 was $1.12 and $0.96, respectively, at the high end of guidance.
Income from continuing operations attributable to CVS Caremark for the year increased 18.8% to $4.6 billion. Excluding a gain from a legal settlement and the loss on early extinguishment of debt, adjusted EPS increased 15.7% in 2013 to $3.96, at the high end of guidance.
“I’m very pleased with our fourth-quarter results, with adjusted earnings per share coming in at the high end of our guidance at $1.12 per share, capping off a terrific year,” Merlo said. “For full year 2013, we delivered strong growth in revenues, gross margins, operating margins and earnings across the CVS Caremark enterprise.”
No comments found